An advisory panel at the National Institutes of Health (NIH) has approved a proposal to use the gene-editing technology CRISPR on human cells. It’s the first trial involving humans to be approved in the U.S.
Researchers at the University of Pennsylvania want to use CRISPR on immune system cells from approximately 18 people with cancer to ultimately help improve treatment. The first trial will test whether CRISPR is safe to use in people. The plan is for researchers to remove immune cells from people with melanoma, sarcoma or myeloma and edit them with CRISPR; the cells will then be put back into the men and women to see how they react.
The trial—which still needs to get approval from the medical organizations that will conduct it—will be funded by a cancer organization founded by former Facebook president Sean Parker. According to the medical news site STAT, the trial is planned to take place at the University of Pennsylvania, MD Anderson Cancer Center and the University of California, San Francisco.
CRISPR is considered one of the greatest recent breakthroughs in science. As TIME reported in this week’s cover story, the technology holds promise for all kinds of interventions, including removing genetic mutations involved in incurable disease. Read TIME’s story here and watch an explainer on how CRISPR works.
More Must-Reads from TIME
- Introducing the 2024 TIME100 Next
- Sabrina Carpenter Has Waited Her Whole Life for This
- What Lies Ahead for the Middle East
- Why It's So Hard to Quit Vaping
- Jeremy Strong on Taking a Risk With a New Film About Trump
- Our Guide to Voting in the 2024 Election
- The 10 Races That Will Determine Control of the Senate
- Column: How My Shame Became My Strength
Contact us at letters@time.com